期刊文献+

Poloxamer 407诱导昆明种小鼠高血脂动物模型的建立(英文) 被引量:4

Poloxamer 407-induced hyperlipidemia animal model in Kunming mice
暂未订购
导出
摘要 【目的】高血脂是公认的心血管疾病的危险因素,本实验拟建立一种昆明小鼠通过注射poloxamer 407而形成高血脂的动物模型。【方法】雄性昆明小鼠随机分为对照组和poloxamer 407组。动物禁食过夜后,一次性腹腔注射poloxamer 407(0.3 g/kg),于注射前及注射后的3、6、24、48及72 h,分别取血测定血中的甘油三酯和胆固醇含量。【结果】poloxamer 407可使昆明小鼠的血甘油三酯和血胆固醇分别升高至基础值的40倍和5倍,且高血脂状态至少能维持72 h以上。【结论】Poloxamer 407能诱导昆明小鼠形成高血脂模型。 【Objective】 Hyperlipidemia is a well-established risk factor for cardiovascular morbidity.We attempted to develop a chemically-induced hyperlipidemic animal model in Kunming mice,using poloxamer 407.【Methods】 Male Kunming mice were randomly divided into 2 groups:control group without any intervention and poloxamer 407 group.After fasted overnight,a bolus of poloxamer 407(0.3 g/kg) was intraperitoneally injected into mice,and blood triglyceride and cholesterol were measured at 0,3,6,24,48 and 72 h after the injection.【Results】 Poloxamer 407 caused the increase of blood triglyceride more than 40-fold and cholesterol 5-fold.And this hyperlipidemic effect of poloxamer 407 lasted up to 72 h after injection.【Conclusions】 Poloxamer 407 induced Kunming mice may be used as a new hyperlipidemic animal model.
出处 《武警医学院学报》 CAS 2011年第2期85-87,96,共4页 Acta Academiae Medicinae CPAPF
基金 武警医学院院级科研基金项目(WBS200905)
关键词 POLOXAMER 407 昆明小鼠 动物模型 高血脂 Poloxamer 407 Kunming mice Animal model Hyperlipidemia
  • 相关文献

参考文献17

  • 1Shepherd J, Packard CJ. Pharmacological approaches to the modulation of plasma cholesterol[J]. Trends Pharmacol Sci, 1988, 9:326-329.
  • 2Wout ZG, Pec EA, Maggiore J, et al. Poloxamer 407- mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats[J]. J Parenter Sci Technol, 1992, 46:192-200.
  • 3Johnston TP, Coker JW, Paigen B J, et al. Sex does not seem to influence the formation of aortic lesions in the P-407-induced mouse model of hyperlipidemia and atherosclerosis[J]. J Cardiovasc Pharmacol, 2002, 39: 404-411.
  • 4Johnston TP, Punjabi MA, Froelich CJ. Sustained delivery of intedeukin-2 from a poloxamer-407 gel matrix following intraperitoneal injection in mice[J]. Pharm Res, 1992, 9: 425 -434.
  • 5Hom D, Medhi K, Assefa G, et al. Vascular effects of sutained fibroblast growth factors[J]. Ann Otology Rhinol Laryngol, 1996, 105:109-116.
  • 6Wang P, Johnston TP. Sustained-release interleukin 2 following intramuscular injection in rats[J]. Int J Pharm, 1995, 113:73-81.
  • 7Pec EA, Wout ZG, Johnston TP. Biological activity of urease formulated in poloxamer-407 after intraperitoneal injection in the rat[J]. J Pharm Sci, 1992, 81:626-630.
  • 8Johnston TP, Miller SC. Insulin disposition following intramuscular administration of an insulin/poloxamer gel matrix [J]. J Parent Sci Technol, 1989, 43: 279-286.
  • 9Johnston TP, Miller SC. Toxicological evaluation of poloxamers for intramuscular use[J]. J Parent Sci Technol, 1985, 39: 83-88.
  • 10Nutting DF, Tso P. Hypolipidemic effect of intravenous pluronic L-81 in fasted rats with Triton WR-1339: Possible inhibition of hepatic lipoprotein secretion[J]. Horm Metab Res, 1989, 21:113-115.

同被引文献71

  • 1Seiki S,Frishman WH.Pharmacologic inhibition of squalenesynthase and other downstream enzymes of the cholesterolsynthesis pathway:a new therapeutic approach to treatment ofhypercholesterolemia[J] .Cardiol Rev.2009,17(2):70-76.
  • 2Leon C,Wasan KM,Sachs-Barrable K,et al.Acute P-407 ad-ministration to mice causes hypercholesterolemia by inducingcholesterogenesis and down-regulating low-density lipoproteinreceptor expression[J] .Pharm Res.2006,23(7):1597-1607.
  • 3Johnston TP,Baker JC,Jamal AS,et al.Potential downregula-tion of HMG-CoA reductase after prolonged administrationof P-407 in C57BL/6 mice[J] .J Cardiovasc Pharmacol,1999,34(6):831-842.
  • 4Johnston TP.The P-407-induced murine model of dose-con-trolled hyperlipidemia and atherosclerosis:a review of find-ings to date[J] .J Cardiovasc Pharmacol,2004,43(4):595-606.
  • 5Johnston TP,Li Y,Jamal AS,et al.Poloxamer 407-inducedatherosclerosis in mice appears to be due to lipid derange-ments and not due to its direct effects on endothelial cells andmacrophages[J] .Mediat Inflamm,2003,12(3):147-155.
  • 6Johnston TP.The P-407-induced murine model of dose-con-trolled hyperlipidemia and atherosclerosis:a review of findingsto date[J] .J Cardiovasc Pharmacol.2004,43(4):595-606.
  • 7Alshehri AM.Metabolic syndrome and cardiovascular risk[J] .J Family Community Med.2010,17(2):73-78.
  • 8Jones JD,Chambliss ML.Hypertriglyceridemia and coronaryheart disease[J] .Arch Fam Med,2000,9(2):189-190.
  • 9Hopkins PN,Wu LL,Hunt SC,et al.Plasma triglycerides andtype III hyperlipidemia are independently associated with pre-mature familial coronary artery disease[J] .J Am Coll Cardiol,2005,45(7):1003-1012.
  • 10Smith SC Jr,Jackson R,Pearson TA,et al.Principles fornational and regional guidelines on cardiovascular diseaseprevention:a scientific statement from the World Heart andStroke Forum[J] .Circulation,2004,109(25):3112-3121.

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部